# Gregory Harriman

> Gregory Harriman is a seed investor at OptiKira (Wayne) backing Biotechnology and Medical. See 3 investments, check sizes, portfolio. Updated Aug 2026.

- Type: Angel Investor
- Fund: [OptiKira](https://shizune.co/investors/profile/optikira)
- Location: Wayne, United States
- Total investments: 3
- Last investment: Dec 2022
- Lead investor: 100%
- Last updated: Aug 2026
- LinkedIn: https://www.linkedin.com/in/gregory-harriman-m-d-a1249a18

Gregory Harriman is a seed investor at OptiKira in Wayne focused on Biotechnology and Medical. Greg is the president of Main Line Ventures, an investment and consultancy company offering funding, technical expertise, and executive management experience to entrepreneurs and early stage bioscience and healthcare companies in the Mid-Atlantic region. Greg is an accomplished executive with over 20 years of experience with increasingresponsibilities in academic medicine and biopharmaceutical companies. He received his medical degree from the University of California, San Diego and trained at Washington University in St. Louis, MO and the National Institutes of Health in Bethesda, MD. He is board-certified in internal medicine, infectious diseases, and clinical & laboratory immunology. He previously had a successful academic career at the NIH and Baylor College of Medicine, having published over 40 articles and book chapters, receiving NIH and private foundation grant funding, and performing innovative, significant research in immunology, vaccines, and immune-mediated diseases. He is a fellow of the American College of Physicians and is a member of several other professional medical organizations, including the American Academy of Asthma, Allergy & Immunology. He has held leadership positions in several small and large biopharmaceutical companies having global experience in the successful research and development of pharmaceuticals, biologics, medical devices and cell therapies, including a multi-billion dollar product for treatment of immune-related diseases.

## Investment focus

### Industry

| Industry | Investments | Share |
| --- | --- | --- |
| Biotechnology | 2 | 67% |
| Medical | 1 | 33% |
| Health Care | 1 | 33% |
| Health Diagnostics | 1 | 33% |
| Information Technology | 1 | 33% |

### Stage

| Stage | Investments | Share |
| --- | --- | --- |
| Seed | 1 | 33% |
| Funding Round | 1 | 33% |

## Investments

| Company | Description | Amount | Stage | Date | Website |
| --- | --- | --- | --- | --- | --- |
| Senzo | Orphidia is developing a rapid blood diagnostic platform to simultaneously run common lab tests on a portable device. | $1.9M | Seed | Dec 12, 2022 |  |
| Senzo | Orphidia is developing a rapid blood diagnostic platform to simultaneously run common lab tests on a portable device. | $2M | Seed | Jul 21, 2022 |  |
| Opsidio | A biotech company, engages in developing monoclonal antibodies to treat fibrotic and remodeling diseases. The company was founded in 2012 and is headquartered in Bryn Mawr, Pennsylvania . | $500K |  | Sep 25, 2017 |  |

3 of 3 investments shown.

## Co-investors
- [Wellness Coaches USA](https://shizune.co/investors/profile/wellness-coaches-usa) — VC Fund, 2 deals together
- [Abenteuer Ventures](https://shizune.co/investors/profile/abenteuer-ventures) — VC Fund, 1 deal together
- [Mid Atlantic Bio Angels](https://shizune.co/investors/profile/mid-atlantic-bio-angels) — VC Fund, 1 deal together

## About OptiKira

VC Fund



1 contacts available at OptiKira.

| Name | Title | Profile |
| --- | --- | --- |
| Gregory Harriman | Chief Medical Officer | https://shizune.co/investors/profile/gregory-harriman |

## Similar investors

### Similar stage
- [Antler](https://shizune.co/investors/profile/antler-be9c) — VC Fund
- [Alumni Ventures](https://shizune.co/investors/profile/alumni-ventures-group) — VC Fund
- [Right Side Capital Management](https://shizune.co/investors/profile/right-side-capital-management) — VC Fund

## FAQ

### What does Gregory Harriman invest in?

Gregory Harriman invests primarily in Biotechnology, Medical and Health Care startups, most often at Seed and Funding Round stage. Most of the 3 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.

### When did Gregory Harriman last invest?

The most recent investment recorded for Gregory Harriman closed in Dec 2022. Shizune tracks 3 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.

### Is Shizune's investor data accurate?

Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.

# About Shizune
Shizune.co is an investor database. Core features:
- 48,091 startup investors (angels, VCs, accelerators, and others)
- Email, phone, LinkedIn (for intros), socials, and other contact data
- Updated daily from public funding news
- CSV and Excel export

The User can access the full database FOR FREE after signing up: shizune.co